Navigation Links
Ferring Pharmaceuticals' EUFLEXXA(TM) to Serve as Sponsor for Sprint Force America Masters Track Club
Date:4/18/2008

PARSIPPANY, N.J., April 18 /PRNewswire/ -- Ferring Pharmaceuticals Inc. has announced that its hyaluronic acid (HA) therapy, EUFLEXXA(TM) (1% sodium hyaluronate), will serve as the sponsor for masters track club Sprint Force America.

"Sprint Force America exemplifies a commitment to active aging," said Alex Drigan, Product Director, EUFLEXXA(TM). "We support this team's dedication to the sport of track and believe that they can inspire others who want to continue doing what they love, regardless of age."

Renowned for their successes in the arena of masters track, Sprint Force America is based in New York and is comprised of male sprinters aged 40-79. The club competes at many national events, including the Penn Relays, the Summer National Senior Games, and the United States Track and Field masters nationals, as well as at international championships.

"We are thankful to EUFLEXXA(TM) for this amazing sponsorship," said Ed Gonera, President and Co-Founder of Sprint Force America. "As a team, we have never believed that age had to affect our ability to compete and we appreciate that our new sponsor supports us in our mission to prove that to the rest of the world."

About EUFLEXXA(TM)

EUFLEXXA(TM) (1% sodium hyaluronate) is the first and only non-avian derived hyaluronic acid approved in the U.S. for the treatment of pain caused by knee osteoarthritis and continues to be the fastest growing brand of HA on the market.(1) EUFLEXXA(TM) is indicated for a three-injection treatment regimen for patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics (e.g., acetaminophen). In a prospective, randomized, double-blind, head-to-head study versus the market leading HA therapy, significantly more patients were "pain-free" and "symptom-free" with EUFLEXXA(TM).(2)

The process used to manufacture EUFLEXXA(TM) produces the HA that most closely resembles the HA in healthy human synovial fluid and the most highly purified HA product available today. In addition, since it is not derived from an avian source (chicken or rooster combs), the risk of reactions related to avian proteins is eliminated.(3-8)

EUFLEXXA(TM) received PMA approval from the U.S. Food and Drug Administration (FDA) on December 3, 2004, and became available to the public on November 8, 2005. For more information, visit http://www.EUFLEXXA.com.

(1) IMS National Sales Perspective Data, February 2008

(2) Kirchner M, Marshall D. A double-blind randomized controlled trial comparing alternate forms of high molecular weight hyaluronan for the treatment of osteoarthritis of the knee. Osteoarthritis Cartilage. 2006; 14:154-162.

(3) Schiavinato A, Finesso M, Cortivo R, & Abatangelo G. Comparison of the effects of intra-articular injections of Hyaluronan and its chemically cross-linked derivative (Hylan G-F20) in normal rabbit knee joints. Clin Exp Rheumatol. 2002; 20: 445-454.

(4) Goomer RS, Leslie K, Maris T, & Amiel D. Native hyaluronan produces less hypersensitivity than cross-linked hyaluronan. Clin Orthop Relat Res. 2005; 434: 239-245.

(5) Leopold SS, Warme WJ, Pettis PD, & Shott S. Increased frequency of acute local reaction to intra-articular hylan GF-20 (synvisc) in patients receiving more than one course of treatment. J Bone Joint Surg Am. 2002; 84-A: 1619-1623.

(6) Puttick MP, Wade JP, Chalmers A, Connell DG, & Rangno KK. Acute local reactions after intraarticular hylan for osteoarthritis of the knee. J Rheumatol. 1995; 22: 1311-1314.

(7) Pullman-Mooar S, Mooar P, Sieck M, Clayburne G, & Schumacher HR. Are there distinctive inflammatory flares after hylan g-f 20 intraarticular injections? J Rheumatol. 2002; 29: 2611-2614.

(8) Chen AL, Desai P, Adler EM, & Di Cesare PE. Granulomatous inflammation after Hylan G-F 20 viscosupplementation of the knee: a report of six cases. J Bone Joint Surg Am. 2002; 84-A: 1142-1147.


'/>"/>
SOURCE Ferring Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Ferring Announces $10,000 Grand Prize Winner of 2007 My Little Miracle Essay Contest
2. Access Pharmaceuticals Announces New Data on Angiolix(R)
3. Lotus Pharmaceuticals, Inc. Announces Fourth Quarter and Fiscal Year 2007 Results
4. Lotus Pharmaceuticals, Inc. Announces Conference Call to Discuss Fourth Quarter and Fiscal Year 2007 Results
5. Sunesis Pharmaceuticals Presents Nonclinical Data on SNS-595 at the Annual Meeting of the American Association for Cancer Research
6. Alexion Pharmaceuticals Invites You to Participate in its First Quarter 2008 Results Conference Call and Web Cast
7. Access Pharmaceuticals to Present New Data on ProLindac(TM) at the AACR Annual Meeting 2008 Conference
8. ISTA Pharmaceuticals Announces Receipt of Subpoena Relating to Promotional Practices for XIBROM(TM)
9. Aida Pharmaceuticals, Inc. Announces New Antibiotic Drug Under Development
10. Bayer HealthCare Pharmaceuticals, Amerinet Extend Contrast Media Agreement
11. Idenix Pharmaceuticals to Present at the Canaccord Adams Hepatitis C Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet ... product that was developed to enhance the health of felines. The formula is all-natural ... two main herbs in the PawPaws Cat Kidney Support Supplement Soft Chews ...
(Date:6/25/2016)... ... ... The temporary closing of Bruton Memorial Library on June 21 due to a possible lice ... overlooked aspect of head lice: the parasite’s ability to live away from a human host, ... a necessary one in the event that lice have simply gotten out of control. , ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, ... Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments in ... the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, ... at his family verbally and physically. , “When something upset him, he couldn’t control his ... it. He would throw rocks at my other children and say he was going to ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and ... that call for a minimum wage raise to $12 an hour by 2020 and then ... will restore the lost value of the minimum wage, assure the wage floor does not ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... HILLS, Calif. , June 23, 2016 Any ... the many challenges of the current process. Many of them ... because of the technical difficulties and high laboratory costs involved. ... have to offer it at such a high cost that ... afford it. Dr. Parsa Zadeh , founder ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
(Date:6/23/2016)... 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered ... Latin America . ... ... ... ...
Breaking Medicine Technology: